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Abstract
Background: For many women, the monthly suffering induced by menstrual “cramps” is severe enough to
profoundly disrupt their quality of life. In the case of primary dysmenorrhea, a condition related to premenstrual
syndrome (PMS), intense uterine contractions are thought to trigger moderate to intense pain despite the absence
of an underlying infection or other medically-identifiable disease states. The associated uterine hyper-contractility
is reminiscent of labor, and associated pain is likely to be mediated by the release of prostaglandins, leukotrienes
and the infiltration of leukocytes that normally accompany the breakdown of the endometrial lining.
Standardized extracts of Vitex agnus-castus berries (VAC extracts of chaste tree, or chaste berries) are clinically
effective in treating the symptoms of PMS, yet the mechanisms of how the chemically complex mixture acts are
largely unknown.
Methods: Using an in vivo dysmenorrhea model rats were treated with 10 mg/kg estradiol-benzoate i.p. once daily
for 12 days and with 2.1, 10.3 or 20.7 mg/kg VAC dry extract p.o. once daily for 7 days prior to induction of convulsions.
Uterine contractions where induced with 2 IU/kg oxytocin i.p., followed by monitoring of abdominal convulsions and
signs of pain on the last day of the experiment. Moreover, in vitro methods were applied that are described in the
methods section.
Results: Here, we show that the VAC herbal dry extract BNO 1095 (commercially available as Agnucaston®) targets the
uterine myometrial tissue and inflammatory signaling molecules of associated migratory/inflammatory cells. Specifically,
BNO 1095 dose-dependently inhibited oxytocin-induced uterine contractions in a rat dysmenorrhea model in vivo and
drug-induced contractions in isolated human and rat uterine tissue in vitro. Furthermore, BNO 1095 showed a promising
anti-inflammatory capacity by potently inhibiting 5-lipoxygenase activity and leukotriene production and by reducing
the production of reactive oxygen species and inflammatory cytokines in vitro.
Conclusion: These results provide evidence that BNO 1095 effectively treats menstruation-related complaints including
primary dysmenorrhea.
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Background
Primary dysmenorrhea refers to menstrual cramping in
the absence of pelvic pathology [1] and is closely linked to
a large group of related menstrual conditions that are
collectively termed premenstrual syndrome (PMS) [2]. Pri-
mary dysmenorrhea represents a common gynecological
complaint especially in young women, with a prevalence
estimated to be as high as 40–50 % in women from this
age group [1]. The intensity of pain associated with uter-
ine cramps in affected women may range from moderate
to severe, and cramps are frequently accompanied by back
pain, nausea, vomiting and diarrhea. In some cases, the
suffering in affected women prevents them from working,
going to school, or normal daily activities.
Physiologically, the pain is most intense in the days
just prior to menstrual flow, and has been proposed to
arise from at least three temporally-related biological
processes. First, the spasmodic uterine contractions in
affected women are often more intense, more frequent,
and of longer duration compared to non-dysmenorrheic
women, and in some cases are described as “labor-like”
[1]. Second, these uterine contractions may constrict the
oxygenated blood supply by vasoconstriction within the
endometrium, leading to enhanced cell death, ischemia [3]
and the production of reactive oxygen species (ROS).
Finally, even in the absence of an infection, there is a con-
comitant “immune-like” influx of inflammatory/migratory
cells including mast cells, eosinophils, neutrophils, and
macrophages immediately prior to menses that likely
assists in the breakdown of endometrial tissue through the
release of proteases and pro-inflammatory prostaglandins
(PGs), leukotrienes, cytokines, and chemokines [3–6].
While these three processes plausibly act in concert to in-
tensify the pain experienced during menstrual cramping,
molecular details of how this process occurs are complex
and poorly understood [1].
Amongst various pro-inflammatory mediators, PGF2α
and PGE2 are known to play a central role in modulating
uterine contraction and vasoconstriction in non-pregnant
and pregnant females, respectively. Intrauterine admin-
istration of PGF2α (but not PGE2) during the secretory
phase of the menstrual cycle has been shown to in-
crease uterine contractility, and implicates this PG as a
key player in primary dysmenorrhea and pain [3, 7].
There are also highly complex interactions between
hormones and mediators, basal body temperature, sleep
patterns, and the central nervous system which are not
completely understood [8, 9].
In one possible molecular scheme for primary dysmen-
orrhea, the withdrawal of estrogen and progesterone leads
to pro-inflammatory and pro-contractile cascades, as well
as a reduction in superoxide dismutase (SOD) enzyme
levels [10] that normally keep ROS levels low and protect
cells against ROS-induced damage [4]. The menstrual
cycle-dependent increase in ROS production activates
transcription factor NF-kB (nuclear factor kappa-light-
chain-enhancer of activated B cells), resulting in increased
prostaglandin (especially PGF2α), chemokine and pro-
inflammatory cytokine production [4, 11]. Finally, PGF2α-
induced uterine contraction and vasoconstriction leads to
hypoxia and pain in the respective myometrial tissue.
This, together with the expression of pro-inflammatory
mediators, used for (and by) the recruitment and activa-
tion of leukocytes results in inflammation, tissue break-
down and ultimately a characteristic menstrual bleeding
[4, 6, 12], after which the pain tends to subside.
Nonsteroidal anti-inflammatory drugs (NSAIDs, such
as naproxen sodium or ibuprofen) are widely used to
treat PMS and primary dysmenorrhea by reducing PG
production via the inhibition of cyclooxygenases (COX-1
and COX-2). However, most prescription-free NSAIDs
can be associated with gastrointestinal side effects such
as nausea and gastric ulceration as well as renal dysfunc-
tion [2]. Also 10–30 % of dysmenorrheic women are not
responsive to COX inhibitors [13], suggesting the role of
other mediators in this condition. For example, an eleva-
tion of leukotrienes observed in women with primary
dysmenorrhea has been suggested to contribute to uter-
ine hypercontraction in humans [14] and as shown in a
guinea pig experimental model [15]. However, no medi-
cinal products acting on the 5-lipoxygenase pathway
have been approved for treatment of PMS so far.
From the women’s perspective, effective alternatives,
particularly herbal medicines with fewer side effects are
preferred [16] to treat PMS-related symptoms. Fruits of
Vitex agnus-castus tree, also known as chasteberry, have
traditionally been used [17] to treat minor symptoms
related to the monthly pain, swelling, and mood disor-
ders that are collectively termed PMS [2]. Standardized
herbal extracts from Vitex agnus-castus fruits (VAC dry
extracts) are recognized and sold in Europe as “well-
established use” herbal medicinal products that are ef-
fective for relief of PMS with fewer side effects than
NSAIDs. The efficacy and safety of VAC dry extracts in
treating PMS symptoms such as irregular menstruation
and breast pain (mastodynia) have been confirmed by
several controlled clinical studies [18–21].
The mechanism of action of VAC herbal extracts in
treating menstrual symptoms has not been completely
elucidated, perhaps due to the large number of poten-
tially active extract constituents, including iridoids,
flavonoids, and diterpenes [22–26]. For example, a large
body of evidence suggests that VAC extracts acts in the
brain at dopamine D2 receptors of the hypothalamus/
pituitary gland axis to inhibit the systemic release of
prolactin from the pituitary gland resulting in the relief
of PMS symptoms [27–31]. However, the potential for
localized anti-contractive and anti-inflammatory actions
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of VAC extracts in primary dysmenorrhea has not been
investigated up to now.
Therefore, in the present studies, we investigated the
ability of the standardized VAC extract BNO 1095 (com-
mercially-available as Agnucaston®) to modulate a number
of potential mechanisms responsible for dysmenorrhea
using in vivo, in vitro, and enzymatic assays, with a special
emphasis on uterine contraction, pain, and the production
and release of the pro-inflammatory molecules PGs,
leukotrienes, cytokines and ROS.
Methods
Materials and reagents
The VAC dry extract BNO 1095 (DER 7–11:1) is commer-
cially available as Agnucaston® and was provided by
Bionorica SE, Neumarkt, Germany. For in vitro studies,
solubilization of the test item was obtained by resuspen-
sion in 50 % ethanol (v/v) at a concentration of 40 mg/ml
and homogenized by 5 min of vortexing, followed by a
30 min incubation at room temperature (RT) in an
ultrasonic bath. The suspension was centrifuged at 3000 g
for 10 min at RT and the supernatant was used immedi-
ately for the experiments.
Unless otherwise specified, all reagents were obtained
from Sigma-Aldrich (Taufkirchen, Germany).
In vivo measurements of uterine contraction, pain, and
locomotor sedation in a rat dysmenorrhea model
Nulliparous, non-pregnant female Sprague Dawley rats
were purchased at the age of 12 to 14 weeks from
Charles River (Sulzfeld, Germany) and housed under
specific pathogen-free conditions, with sterilized water
and food given ad libitum. 12 days prior to the start of
the experiments, the animals were randomly allocated
to approximately-equal control (saline), treatment (BNO
1095), or comparator (carprofen) groups (n = 12–14 per
group) and acclimatized in groups of 4 animals to their
new cages. On Day 1 to Day 12, all animals were i.p.
injected once-daily with 10 mg/kg body weight estradiol-
benzoate. On Day 6 to Day 12, animals assigned to the
treatment groups were dosed once-daily with an oral sus-
pension (in sterile water) of BNO 1095 via oral gavage at
one of three doses: 2.1 mg/kg body weight (comparable to
five times the recommended human equivalent dose, 5×
HED), 10.3 mg/kg body weight (25× HED) or 20.7 mg/kg
body weight (50× HED) in a volume of 10 ml/kg, while
animals of the control group received an equal amount of
water. On Day 12, animals from the control, treatment
and comparator groups received the following (all
volumes equal between groups, respectively): water p.o.
and a subcutaneous (s.c) injection of saline; BNO 1095
extract p.o. 3 hours after the last application of estradiol-
benzoate and an s.c. injection of saline, or p.o. water and a
s.c. injection of 5 mg/kg body weight of the NSAID
carprofen (Pfizer, Berlin, Germany).
On Day 12, 1 hour after the vehicle or carprofen s.c.
injection, oxytocin (10 I.U./ml, Hexal AG, Holzkirchen,
Germany) was applied i.p. at a dose of 2,000 mI.U./kg
(3.33 μg/kg) body weight to the animals of all groups to
induce uterine contractions. Latency time and number
of abdominal convulsions, indicated by writhings, after
administration of oxytocin were monitored to estimate
the degree of myometrial stimulation. In addition, the pain
reaction was quantified according to the grimace scale as
described by Sotocinal et al. [32], a method chosen due to
its ease of automation and its ability to differentiate
between spontaneous and evoked (e.g., in response to
abdominal prodding) pain. Briefly, changes in orbital tight-
ening, nose/cheek flattening, ear change and whisker
change were quantified in a scale of 0 (normal), 1 (moder-
ate) or 2 (obvious). In addition to measurements of
uterine contraction and pain, a beam walking test was
performed, as described by Goldstein et al. [33] with mod-
ifications according to Flierl et al., [34] to analyze gait and
latency while crossing a wooden bar to measure any po-
tential influence of BNO 1095 or carprofen administration
on motor coordination (a subjective scale from 0 to 16,
where a score of 7 = normal and 3 =motor disorder) or
sedation (measured by the amount of time between pla-
cing the animal on the beam and moving forward to cross
the bar).
Rat experiments were conducted in accordance with the
regulations for the care and use of laboratory animals and
approved by the institutional animal ethics committee: a)
EU: Directive 2010/63/EU of the European Parliament
and of the Council of September 22, 2010 on the Protec-
tion of Animals Used for Scientific Purposes; b) Directive
CETS No. 123 (ETS 123): European Convention for the
Protection of Vertebrate Animals used for Experimental
and Other Scientific Purposes Council of Europe (1986),
Appendix A (2006).
In vitro organ bath contraction experiments using excised
rat uterine tissue
For the analysis of anti-convulsive activity using isolated
rat uterine strips, female nulliparous Sprague–Dawley
rats with body weights in the range of 250–275 g at de-
livery were obtained from Charles River Laboratories
(Saint Germain sur l’Arbresle, France). Rats were treated
with diethylstilbestrol (0.25 mg/kg, i.p.) 18 h prior to ex-
periment (to synchronize hormonal conditions). Diethyl-
stilbestrol was dissolved at the concentration of 0.5 mg/
ml in corn oil (batch MKBH4894V, Sigma-Aldrich) and
a volume of 0.5 ml/kg was injected. On the day of the
experiment, rats were sacrificed by CO2 asphyxiation.
The uterus was excised, cleaned from connecting tissues
and longitudinal strips of uterus were rapidly dissected
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from each horn (2 strips per horn) and placed in 5 ml
organ baths containing oxygenated Krebs solution of the
following composition (in mM): NaCl 114, KCl 4.7, CaCl2
2.5, MgSO4 1.2, KH2PO4 1.2, NaHCO3 25, glucose 11.7
(pH 7.4, aerated with 95 % O2 and 5 % CO2 at 37 °C).
Uterine tissues were allowed to equilibrate at 1.0 g resting
tension for at least 60 min, during which time the Krebs
solution was replaced every 15 min and the tension read-
justed if necessary. Following this equilibration period,
myometrial contractions were induced by adding 0.5 nM
(0.5 ng/ml) oxytocin, 1 μM (354.5 ng/ml) PGF2α or 50 nM
(54.2 ng/ml) vasopressin to the baths. After contractions
stabilized in amplitude and frequency, cumulative
concentration-response curves to 10–1000 μg/ml BNO
1095 (dry extract solubilized as described above), positive
control ritodrine (Sigma-Aldrich, Saint-Quentin Fallavier,
France) and the vehicle control (aqueous ethanol solution)
were recorded. Ethanol concentration in organ baths were
at most 0.5 % for the maximal drug (or extract) concentra-
tions tested. Data are presented as percent of control
(relaxation before addition of test substance or vehicle).
All experiments using rat uterine tissue were performed
in accordance with French legislation concerning the
protection of laboratory animals and in accordance with a
currently valid license for experiments on vertebrate
animals, issued by the French Ministry for Agriculture
and Fisheries.
In vitro organ bath contraction experiments using excised
human uterine tissue
Samples of human uterus, obtained with informed con-
sent, were taken from non-pregnant pre-menopausal
donors. All uterine strips (approximately 15 mm length),
were suspended in 25 ml organ baths containing physio-
logical salt solution (PSS, 119.0 mM NaCl, 4.7 mM KCl,
1.2 mM MgS04, 24.9 mM NaHCO3, 1.2 mM KH2PO4,
2.5 mM CaCl2 and 11.1 mM glucose), aerated with 95 %
O2 and 5 % CO2 and maintained at approximately 37 °C.
One side of the tissue strip was attached to an isometric
transducer that records changes in tension. The uterine
strips were allowed to equilibrate for at least 30 min.
Uterine strips were then normalized to a standard pas-
sive tension (20 mN, approximately 2 g) to reduce signal
variability prior to pharmacological intervention. The
strips were then allowed to equilibrate for at least 1
hour, with washes with PSS every 15 min, to allow the
development of spontaneous contractions. Any uterine
strips failing to produce spontaneous contractions after
tension was applied in the organ bath were rejected.
0.2 μM (0.2 μg/ml) oxytocin was added to increase the
size and frequency of the spontaneous contractions. After
contractions stabilized in amplitude and frequency, cumu-
lative concentration-response curves to 10–400 μg/ml
BNO 1095, the dihydropyridine calcium-channel blocker
isradipine (positive control) and the vehicle control
(aqueous ethanol solution) were recorded. The concen-
tration of ethanol in organ baths was within the range
of 0.013 to 0.5 % for the maximal concentration tested.
Data are presented as percent of control (relaxation
before addition of test substance or vehicle).
Inhibition of purified 5-lipoxygenase (5-LO) and cellular
leukotriene biosynthesis in isolated human monocytes
In the cell-free (purified enzyme) assay, human recom-
binant 5-lipoxygenase (5-LO) was expressed in E. coli
Bl21 (DE3) cells that were transformed with pT3–5LO,
and purified by ATP-agarose column [35]. For determin-
ation of the enzymatic activity, the purified enzyme was
added to 1 ml of a 5-LO assay mix (PBS, pH 7.4, 1 mM
EDTA, 1 mM ATP). After incubation for 10 min at 4 °C
with vehicle (0.5 % ethanol) or BNO 1095, samples were
pre-warmed for 30 s at 37 °C in the presence of 2 mM
CaCl2 followed by addition of 20 μM (6.1 μg/ml) arachi-
donic acid. The reaction was stopped after 10 min at
37 °C by addition of 1 ml ice-cold methanol, and
200 ng PGB1 were added. Formed metabolites were ex-
tracted and analyzed by HPLC as previously described
[36]. 5-LO products include LTB4 all-trans isomers and
5-H(p)ETE. Results are reported as percentage of
vehicle control.
Analysis of 5-LO inhibition in a cell-based assay was
performed using human monocytes isolated from freshly
withdrawn peripheral blood samples. Blood samples were
obtained from consenting healthy donors (Institute of
Transfusion Medicine, University Hospital Jena, Germany)
who had declared that they had not taken any anti-
inflammatory drugs within 10 days of providing the sam-
ple. The venous blood was centrifuged at 4,000 g for
20 min at 20 °C, PBMC were isolated by dextran sedimen-
tation and centrifugation on Nycoprep cushions, and
monocytes were collected by adherence as described
above. Monocytes were finally resuspended in PGC buffer
at the cell density of 2 × 106 cells/ml and incubated for
15 min at 37 °C with BNO 1095, vehicle or zileuton (3 μM
or 0.71 μg/ml). Then, cells were stimulated at 37 °C with
the Ca2+-ionophore A23187 (5 μM or 2.6 μg/ml). After
10 min, the reaction was stopped on ice and samples were
centrifuged at 500 g for 10 min at 4 °C. Supernatants were
collected and formed LTC4 was analyzed by ELISA (Enzo
Life Sciences GmbH, Lörrach, Germany) according to
manufacturer’s instructions. For analysis of LTB4, all trans
LTB4 and 5-H(p)ETE using HPLC, 750 μL supernatant
were mixed with 750 μL methanol and 22.5 μL of 1 N
HCl, 150 ng PGB1, and 375 μL of PBS were added.
Formed 5-LO products were extracted, analyzed by HPLC
as described elsewhere [36] and presented as sum of all 5-
LO products (i.e., LTB4, its all-trans isomers, and 5-
H(p)ETE). Results are reported as normalized percentages
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vs. vehicle control (=100 %). Data represent three inde-
pendent experiments, each collecting single data points.
Analysis of cytokine release from cultured human PBMCs
Cryopreserved PBMCs (Eurofins Panlabs Inc., Bothwell,
WA, USA) were thawed and seeded into 96 well plates
in culture media (RPMI 1640, 10 % FBS, 1 % penicillin/
streptomycin, 2 mM L-alanyl-L-glutamine) at a cell
density of 5 × 104 cells/well. After incubation for 1 h at
37 °C, 10–300 μg/ml BNO 1095, vehicle control (0.3 %
ethanol final concentration) or the positive control 100
nM (39.25 ng/ml) dexamethasone was added and incu-
bated again for 1 h at 37 °C. After addition of 50 ng/ml
LPS, PBMCs were incubated for 24 h at 37 °C. Collected
supernatants were analyzed for cytokines using Procarta-
Plex multiplex bead arrays for human IL-1β, IL-6, IL-8,
MIP-1α and TNFα (Affymetrix, Santa Clara, CA, USA).
Data represent two independent experiments in dupli-
cate measurements.
Reactive oxygen species (ROS) release assay from isolated
human macrophages
Human monocytes were isolated as described above. To
obtain macrophages, the freshly isolated monocytes were
incubated for 6 days with 20 ng/ml M-CSF at 37 °C in a
5 % CO2 atmosphere. For analysis of ROS formation,
cells (human macrophages or neutrophils) were preincu-
bated with the peroxide-sensitive fluorescence dye 2′,7′-
dichlorofluorescein-diacetate (1 μg/ml) for 10 min at
37 °C. Then, 5–75 μg/ml (macrophages) or 1 – 100 μg/
ml (neurophils) of the test compound or vehicle (con-
taining 0.5 % ethanol) was added and after 10 min, cells
were stimulated by 100 nM (61.7 ng/ml) (macrophages)
or 1.62 μM (1 μg/ml) (neutrophils) phorbol 12-myristate
13-acetate (PMA). The fluorescence emission at 530 nm
was measured after excitation at 485 nm in a thermally
controlled (37 °C) 96-or 24-well plate in a spectrofluo-
rometer. Diphenylene iodonium (DPI, 5 μM or 1.4 μg/
ml) was used as control inhibitor. Data represent three
independent experiments, each collecting single data
points.
DPPH colorimetric radical scavenging (ROS-reduction) assay
The reaction of DPPH (2,2-diphenyl-1-picrylhydrazyl)
with an antioxidant or reducing compound produces the
corresponding hydrazine DPPH2, which is assessed by
monitoring the photometric color change from purple to
yellow. Briefly, 0.1–300 μg/ml BNO 1095 was added to
100 μl ethanol (blank controls) or to 100 μl of a solution
of the stable free radical in ethanol buffered with acetate
to pH 5.5 (50 μM, corresponding to 19.7 μg/ml), in a 96-
well plate. Ascorbic acid (100 μL of 50 μM (8.8 μg/ml) so-
lution ascorbic acid in ethanol, i.e. 5 nmol ascorbic acid)
was used as reference compound. The absorbance was
read at 520 nm after 30 min incubation under gentle shak-
ing in the dark. Radical scavenging activity is expressed as
% absorption of the subtracted blank control [A520 nm
(DPPH, 50 μM+ extract)-A520 nm (blank)] vs. [A520 nm
(DPPH, 50 μM+ vehicle) - A520 nm (blank)]. Data repre-
sent three independent experiments, each collecting single
data points.
Statistical analysis
Unless otherwise stated, all values are presented as
mean ± standard error of the mean (SEM) of at least
two independent experiments analysed in triplicate mea-
surements. Statistical significance was assessed using one-
way ANOVA followed by Dunnett’s multiple comparison
post-hoc test and a p-value criteria of ≤ 0.05 was used to
assess statistical significance. For in vitro experiments,
IC50 values were calculated by non-linear regression using
the equation (Y = 100/(1 + 10^((LogEC50-X)*HillSlope)),
X = log of dose or concentration, Y = normalized response
(0–100 %)). Curve fitting, IC50 value calculation, and
statistical analyses were performed with GraphPad Prism
version 5.04 (GraphPad Software Inc., San Diego, CA).
Results
BNO 1095 dose-dependently reduced the number of
oxytocin-induced uterine contraction and resulting uter-
ine pain without causing sedation or locomotor deficits
Primary dysmenorrhea is characterized by severe pain
during intense uterus contractions. Nulliparous rats
were treated for 1 week by daily oral gavage with 2.1–
20.7 mg/kg BNO 1095 dry extract (corresponding to 5
to 50 times the recommended human equivalent dos-
age, or 5× to 50× HED) prior to induction of uterine
cramps by i.p. injection of 2,000 mI.U./kg (3.33 μg/kg)
body weight oxytocin. Immediately after oxytocin injec-
tion, signs of uterine contractions and pain were moni-
tored and recorded. Specifically, the latency until onset,
total number of contractions (abdominal convulsions,
writhings), and perceived pain (quantified according to
the “grimace scale”, with a maximal score of 2 represent-
ing obvious pain) was compared among vehicle control,
treatment (BNO 1095), and comparator (carprofen, an
NSAID analgesic) groups.
Treatment with up to 20.7 mg/kg of BNO 1095 did not
significantly alter the latency until the start of convulsions
when compared to either the vehicle control or 5 mg/
kg s.c. injection of the carprofen comparator groups (data
not shown). However, progressively increasing doses of
BNO 1095 (2.1 up to 20.7 mg/kg body weight) (Fig. 1a)
led to a maximal reduction of convulsions by about 67 %
versus the vehicle control group (mean number of convul-
sions ± SEM: vehicle, 9.72 ± 1.61; 20.7 mg/kg BNO 1095:
3.23 ± 1.16; carprofen: 1.77 ± 0.99) that was significantly
different compared to the vehicle control (p < 0.05) and
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roughly comparable to the inhibition seen with the car-
profen group at the 20.7 mg/kg BNO 1095 dose.
In the measurement of perceived pain (Fig. 1b), no
values from the BNO 1095 or comparator groups reached
statistical significance versus the control group, but
20.7 mg/kg BNO 1095 showed numerical decreases in the
mean grimace scale values for orbital tightening, nose/
cheek flattening, and whisker change reaching similar
levels to those seen with carprofen. The mean value for
ear change was not markedly reduced by BNO 1095 when
compared to carprofen.
In the beam walking test (Fig. 1c), animals of all tested
groups crossed the beam with a normal gait and with
less than two foot-slips per beam crossing. In comparing
the beam walk score for rats from the vehicle control,
20.7 mg/kg BNO 1095, and 5 mg/kg carprofen groups,
rats from the BNO 1095 group (8.75 s ± 1.05) started to
cross the beam 2 times faster than rats from the carpro-
fen group (16.62 s ± 3.32) suggesting that rats from the
latter group seem to be more sedated than the control
(p < 0.05) and BNO 1095 groups. In contrast, the beam
walk score for rats from the vehicle control, 20.7 mg/kg
BNO 1095, and 5 mg/kg carprofen groups (not shown)
indicated that the gait of all three groups were normal
and almost identical (7.0 ± 0, 7.0 ± 0, 6.92 ± 0.08, respect-
ively). Taken together, these results indicate that while
rats treated with 20.7 mg/kg BNO 1095 showed a reduc-
tion of the number of contractions and a decrease in pain
that was roughly comparable to that of 5 mg/kg carprofen,
BNO 1095 at this dose did not induce noticeable sedation
or other impairments in motor coordination.
BNO 1095 inhibited drug-induced contractions in excised
rat and human uterine tissue
To study the direct effects of BNO 1095 on uterine
contractions, isolated uterus strips from nulliparous
rats were mounted in organ baths and smooth muscle
contractions were induced by 0.5 nM (0.5 ng/ml) oxy-
tocin (Fig. 2a), 1 μM (354.5 ng/ml) PGF2α (Fig. 2b) or
50 nM (54.2 ng/ml) vasopressin (Fig. 2c). In each case,
addition of 10–400 μg/ml BNO 1095 demonstrated a
concentration-dependent inhibition of contractions of
uterus strips which exhibited a maximal effect (ca.
100 % inhibition of control) that exceeded by far the
maximal inhibition (ca. 20 % inhibition, Fig. 2b) ob-
served with the vehicle control (max. 0.5 % ethanol).
After fitting each respective concentration-response
curve, IC50 values for the ability of BNO 1095 to inhibit
contractions induced by oxytocin, PGF2α, and vasopres-
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Fig. 1 Inhibition of contractions by BNO 1095 in vivo in a rat dysmenorrhea model. Effect of the Vitex agnus castus dry extract BNO 1095 on (a) number
of abdominal convulsions and b the grimace scale after i.p. oxytocin injection. c Latency time until start of beam walking. Data are given as
means ± SEM, n = 12–14. *: p < 0.05, **: p < 0.01, ***: p < 0.001
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In addition, we analyzed the effect of BNO 1095 on
isolated human myometrial strips obtained from
women undergoing uterine resections. Analogous to
the experiments described above, cumulative addition
of 10–400 μg/ml BNO 1095 inhibited 200 nM (0.2 μg/ml)
oxytocin-induced periodic smooth muscle contractions in
a concentration-dependent manner with a curve-fitted
IC50 value of 82 μg/ml (Fig. 3). Note that although
myometrial strips were obtained from apparently healthy
portions of the uterus, a longer preparation time and
transport to the laboratory as for the rat tissue samples
may contributed to the larger basal response elicited by
the vehicle control (up to 40 %) compared to control re-
sponses observed in the rat tissue experiments. As in the
rat tissue experiments, maximal ethanol concentrations in
the vehicle control were 0.5 %.
BNO 1095 did not substantially inhibit purified
phosphodiesterase (PDE) enzyme activity
After confirming the ability of BNO 1095 in an in vivo
rat model and in vitro excised uterine tissue experi-
ments, we further investigated possible mechanisms of
its action. A number of literature sources have suggested
that PDE enzymes, responsible for the conversion of
cyclic AMP (cAMP) into adenosine triphosphate (ATP),
may enhance the properties of intrinsic relaxant mole-
cules, especially in pregnant females. Specifically, human
endometrial stromal cells express the PDE isoforms
PDE4 and PDE8 [37], and PDE4-selective inhibitors such
as rolipram have been shown to have spasmolytic effects
in the myometrium [38–40].
Therefore, we analyzed the BNO 1095 extract regard-
ing its inhibitory effect on the PDE subtypes PDE4B2,
PDE4D1 and PDE8A1. However, for each of the tested
enzymes subtypes, BNO 1095 inhibited PDE activity
only at rather high concentrations, that is, 100 and
300 μg/ml (data not shown), compared to the pro-
nounced ability of BNO 1095 to potently inhibit the
production of leukotrienes, cytokines, and ROS (see
below). Therefore, it appears unlikely that BNO 1095
inhibits uterine contractions via a reduction of PDE ac-




















































































IC50 = 100 µg/ml
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Fig. 2 Concentration-dependent inhibition of drug-induced contraction by BNO 1095 on rat uterine strips. Relaxation of a 0.5 nM (0.5 ng/ml) oxy-
tocin-, b 1 μM (354.5 ng/ml) PGF2α-or c 50 nM (54.2 ng/ml) vasopressin-induced contractions of isolated rat uterus specimens. Up to 0.5 % etha-



























IC50 = 82 µg/ml
Fig. 3 Concentration-dependent anti-convulsive effect of BNO 1095
on human uterine strips. Relaxation of 200 nM (0.2 μg/ml) oxytocin-
induced contractions of isolated human uterus specimens through
BNO 1095. Up to 0.5 % ethanol was present in the vehicle control.
Data are given as means ± SEM, n = 5
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BNO 1095 potently suppresses leukotriene biosynthesis
in human monocytes and inhibits the activity of purified
5-LO in a cell-free assay
Leukotrienes are synthesized from arachidonic acid
involving 5-LO and represent important lipid mediators
of the inflammatory immune response that are known to
accompany menstruation [13, 15, 41]. We therefore
investigated the effect of the extract on 5-LO product
biosynthesis in a cell-free (purified enzyme) and cell-
based (in human monocytes) model.
In a cell-free 5-LO inhibition assay, BNO 1095
concentration-dependently inhibited the activity of
purified 5-LO with an IC50 value of 28.9 μg/ml (Fig. 4a).
These results were confirmed and expanded using a
cell-based assay, where 10–400 μg/ml BNO 1095 inhib-
ited the formation of 5-LO products (LTB4, trans LTB4,
epi-LTB4 and 5-H(p)ETE) with an IC50 value of
22.2 μg/ml and blocked the formation of LTC4 with an
IC50 value of 63.5 μg/ml (Fig. 4b).
BNO 1095 did not substantially reduce COX-mediated
prostaglandin synthesis in isolated human monocytes
and macrophages
We investigated the effects of BNO 1095 on the biosyn-
thesis of PGE2 and TXB2 in human monocyte-derived
macrophages after stimulation with the pro-inflammatory
agent LPS (1 μg/ml). Addition of up to 300 μg/ml BNO
1095 to macrophages after activation by LPS caused no
observable inhibitory effect on the formation of COX-
mediated biosynthesis of PGE2 (LPS + BNO 1095: 70.0 %
± 30.3 vs. LPS alone set to 100 %) and TXB2 (LPS + BNO
1095: 108.4 % ± 20.3 vs. LPS alone set to 100 %) (data not
shown). The BNO 1095 extract (up to 300 μg/ml) also
failed to significantly influence the release of PGF2α from
LPS-stimulated human monocytes (LPS + BNO 1095:
73.2 % ± 5.4 vs. LPS alone: 108.0 % ± 7.4) (data not shown).
These results indicate that BNO does not target the COX
pathway of the arachidonic acid cascade in intact cells.
Analysis of cytokine release from cultured human
peripheral blood mononuclear cells (PBMCs)
Cytokines are potent regulators of inflammation. Ana-
lysis of human PBMCs revealed effective inhibition of
cytokine release after pretreatment with 10–300 μg/ml
BNO 1095 for 1 h prior to stimulation with 50 ng/ml
LPS. As shown in Fig. 5, BNO 1095 concentration-
dependently inhibited the release of IL-1β, IL-6, IL-8,
TNFα and the chemokine MIP-1α (macrophage inflam-
matory protein-1α, or CCL3) with IC50 values of 20.1,
60.7, 98.4, 51.6 and 75.7 μg/ml, respectively. The release
of the major inflammatory cytokine IL-1β was inhibited
at lower concentrations when compared to the other
four molecules, which is of interest, since IL-1β is
known to stimulate PG and leukotriene biosynthesis [13,
42]. Higher BNO 1095 concentrations were required to
inhibit IL-8 secretion, a chemokine known to recruit
neutrophil migration and thought to be important for
the endometrial remodeling during menstruation [43].
BNO 1095 reduced reactive oxygen species (ROS) release
from isolated human macrophages and shows
antioxidant properties in a cell-free assay
Certain phytomedicines have been reported to possess
antioxidant capability, and are thus proposed to be pro-
tective against cell damage mediated by ROS. To test if
BNO 1095 may interfere with ROS production, macro-
phages (Fig. 6a) or neutrophils (Fig. 6b) where analyzed
for their capability to release ROS. A significant reduction
of ROS formation in both cell types after pretreatment
with BNO 1095 for 1 h prior to stimulation with PMA
was observed. The cell-free DPPH radical scavenging
assay demonstrated anti-oxidant activity of the BNO 1095



























































IC50 = 63.5 µg/ml
5-LO products
IC50 = 22.2 µg/ml
A B
Fig. 4 Concentration-dependent inhibition of 5-LO (purified enzyme) activity and 5-LO product formation in human monocytes by BNO 1095. a Cell-
free 5-LO enzyme inhibition by BNO 1095 using purified human recombinant 5-LO. b Inhibition of 5-LO product (sum of LTB4, trans-LTB4, epi-LTB4 and
5-H(p)ETE) formation and LTC4 production by BNO 1095 in a cell-based (human monocyte) in vitro assay. 0.5 % ethanol served as vehicle control. Data
are given as means ± SEM, n = 3
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Discussion
Reduction of contractions and reduction of perceived
pain by BNO 1095
In both humans and animal models, uterus contrac-
tions can be mediated by oxytocin, vasopressin or
PGF2α [44, 45], although the physiological relevance of
each ligand is highly dependent on the implantation
state (e.g., the female is pregnant or non-pregnant) and
the temporal position in the pregnancy or menstrual/
estrous cycle [42]. Other molecules are also important
in the modulation and induction of menstruation, most
notably progesterone and estrogen [4, 6] as well as
PGE2 [3]. While a consensus model underlying primary
dysmenorrhea is still lacking, the clinical use of NSAIDs
and oral contraceptives for the treatment of menstrual
pain [46, 47] and PMS [2] suggest the involvement of
these molecules in these conditions.
In our in vivo animal model system for dysmenorrhea
rats were treated once-daily with 10 mg/kg body weight
estradiol-benzoate to induce endometrial hyperplasia as
a prerequisite for oxytocin-induced dysmenorrhea-like
uterine contractions. It is worth mentioning that estra-
diol is known to induce prolactin secretion [48]. Bigazzi
et al. [49] reported that human prolactin-increased fre-
quency and amplitude of spontaneous contractions of
rat uterus. This is in contrast to the report of Lessing et
al. [50] demonstrating that rat prolactin has no signifi-
cant effect on rat uterine muscle, indicating species
specificity of prolactin. Thus, a potential effect of en-
dogenous prolactin in this model may be negligible.
In our dysmenorrhea model, BNO 1095 decreased the
number of oxytocin-induced uterine contractions and
pain scores as measured by the rat grimace scale. Further
evidence for a spasmolytic action of BNO 1095 was pro-
vided by in vitro experiments with human or rat uterine
tissue strips, where BNO 1095 concentration-dependently
inhibited contractions induced by oxytocin, vasopressin,
or PGF2α. These data are supported by results from a
study by Afifi et al. showing that isoorientin, a flavonoid
found in the VAC whole fruit extract (BNO 1095) [26],
concentration-dependently inhibits contractions of the rat
and guinea pig uterus in vitro [22]. The anti-convulsive ef-
fect may contribute to the beneficial effects of BNO 1095
in relieving pain caused by menstrual cramps. Our results
also complement data from several in vitro studies reveal-
ing a neuroendocrine mode of action of BNO 1095
extracts. Specifically, BNO 1095 extract preparations
demonstrated specific binding to the dopamine D2 recep-
tor [27, 28], which would thereby inhibit prolactin release












































Fig. 5 Concentration-dependent inhibition of inflammatory cytokine
release from human PBMCs by BNO 1095. LPS-induced inflammatory
cytokine release from human PBMCs is inhibited by BNO 1095. Cells
were pretreated with BNO 1095 for 1 h and subsequently stimulated
with 50 ng/ml LPS for 24 h. 0.5 % ethanol served as vehicle control.
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Fig. 6 Analysis of the effects of BNO 1095 on cellular ROS formation and ROS scavenging activity. Effects of BNO 1095 on cellular formation of
ROS in 100 nM (1 μg/ml) PMA-activated human (a) macrophages and b neutrophils. c Anti-oxidative activity of BNO 1095 in a cell-free colorimet-
ric assay. DPI (reference compound), 5 μM (1.4 μg/ml). 0.5 % ethanol was present in the vehicle control. Data are given as means ± SEM, n = 3. *,
p < 0.05, **, p < 0.01, ***, p < 0.001
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hormonal cascade ultimately responsible for a wide range
of menstrual symptoms in women suffering from PMS.
Therefore, BNO 1095 shows not only a systemic, but also
a local action in the uterus to control biological processes
known to be active during menstruation.
Reduction of pro-inflammatory signaling molecules by BNO
1095
At present, it is difficult to determine which molecules
and processes relate to primary dysmenorrhea versus the
normal menstrual cycle, since dysmenorrhea is likely an
“exaggeration” of healthy body processes. However, in
addition to increased uterine contractions, it has also
become increasingly clear that pro-inflammatory mole-
cules and inflammatory cells are thought to play a role
in endometrial breakdown and assist in the eventual
removal of the endometrial lining in the absence of
pregnancy. Although far from being a “disease state”, such
an inflammatory process along with leukocyte recruitment
in the late secretory phase [5] may unfortunately increase
the pain sensitivity and/or uterine contractions via inter-
coupled feedback mechanisms in patients with primary
dysmenorrhea.
In our present study we used a combination of in vitro
cell-based (primary composed of human monocytes,
neutrophils and macrophages) and cell-free (enzymatic,
colorimetric) assays in order to demonstrate inhibitory
actions of BNO 1095 on the pro-inflammatory and pain-
enhancing leukotrienes, cytokines/chemokines, and ROS.
In light of the growing evidence for a role of inflammatory
mediators to affect the immune response in facilitating
endometrial breakdown during menstruation [3, 4, 6, 13,
43, 51], the ability of BNO 1095 to potently inhibit release
of these inflammatory mediators may explain the bene-
ficial effect of this herbal extract in the treatment of
primary dysmenorrhea.
Leukotrienes have been postulated to increase the
sensitivity to pain in the uterus [1, 4, 13, 14, 41] and to
cause uterine contractions [15]. Indeed, higher circulat-
ing levels of LTC4 and LTD4 have been found in the
menstrual blood of women with primary dysmenorrhea
[13, 14] and thus, the inhibition of uterine contraction
via a reduction of these cysteinyl-leukotrienes repre-
sents a plausible molecular mechanism for the BNO
1095 action, as observed in the rat in vivo experiments.
Interestingly, our investigation of the COX-1/2-medi-
ated branch of the arachidonic acid pathway supports
the hypothesis that BNO 1095 does not significantly
inhibit the release of PGE2, PGF2α, or TXB2 in cells
associated with an increased migratory/inflammatory
uterine response during menstruation [3–6].
Finally, our results suggest that antioxidant compounds
within BNO 1095 may reduce pain by scavenging ROS,
which are known to increase PGF2α, chemokine and
pro-inflammatory cytokine production during menstru-
ation. Specifically, ROS in conjunction with copper-zinc
superoxide dismutase (Cu/Zn-SOD) [4, 10] and NF-kB
have been proposed to serve as important signal transduc-
ers between the withdrawal of estrogen and progesterone
and endometrial breakdown via a stimulation of COX-2
expression and promotion of PGF2α release [11].
Anti-inflammatory and anti-oxidative effects have been
previously reported for VAC extracts and several single
VAC constituents [25, 52, 53]. For example, Choudary et
al. demonstrated LO enzyme-inhibiting activity of casticin
in vitro [54], and the flavonoid vitexin inhibited pro-
inflammatory cytokine production and inflammation-
induced pain [23] in an in vivo experimental inflammation
model. This broad anti-inflammatory and anti-oxidative
effects described for VAC extracts and its constituents
could therefore contribute to the beneficial action of VAC
extracts regarding PMS and painful menstrual complaints.
Conclusion
Our in vivo data from an experimental dysmenorrhea
model and in vitro studies using isolated rat and human
uterine specimens revealed significant spasmolytic proper-
ties of BNO 1095 via local actions that are complementary
to the extract’s previously-known neuroendocrine inhib-
ition of prolactin release. Additionally, BNO 1095 showed
potent anti-inflammatory activity in vitro as it suppressed
leukotriene (but not prostaglandin) biosynthesis, cyto-
kine release and ROS production from isolated human
leukocytes. The ability of BNO 1095 to inhibit the
release of these pro-inflammatory molecules from
migratory/inflammatory cells complements the extract’s
spasmolytic action and supports the beneficial effects
described for BNO 1095 for the treatment of menstrual
disorders.
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